Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, randomized, double-blind, active-controlled, multicenter trial of abciximab and bivalirudin in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary interventions [PCI] (ISAR-REACT-4).

Trial Profile

Prospective, randomized, double-blind, active-controlled, multicenter trial of abciximab and bivalirudin in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary interventions [PCI] (ISAR-REACT-4).

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abciximab (Primary) ; Heparin (Primary) ; Bivalirudin
  • Indications Embolism and thrombosis; Myocardial infarction
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ISAR-REACT-4
  • Most Recent Events

    • 25 Sep 2023 Results of Individual Patient Data Meta-Analysis , from MATRIX, VALIDATE-SWEDEHEART, ISAR-REACT 4, ACUITY and BRIGHT; comparing the outcomes of bivalirudin and heparin in patients with non-ST-segment-elevation myocardial infarction undergoing PCI, published in the Circulation
    • 29 Aug 2012 1-Year results presented at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.
    • 23 Nov 2011 Primary endpoint composite of death, larger recurrent myocardial infarction, urgent target vessel revascularisation or mmajor bleed event rates has not been met.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top